Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L9LS for Malaria Prevention
NCT05019729Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of L9LS in malaria (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 4 more. Started Sep 2021; status: completed.
02
Drugs
L9LS
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05019729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019729.